Re­genxbio touts pos­i­tive mid-stage da­ta for Ab­b­Vie-part­nered vi­sion-loss gene ther­a­py, but no de­tailed plans for piv­otal study

Re­genxbio re­leased pos­i­tive in­ter­im da­ta from its Phase II tri­al of its Ab­b­Vie-part­nered vi­sion-loss gene ther­a­py pro­gram, tout­ing “sta­ble” vi­su­al acu­ity …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.